Background
Cancer comprises a diverse mix of diseases occurring in every part of the body and is a leading cause of death in the United States (2) . More than half of cancer cases could be prevented (3) . Surveillance of cancer incidence and mortality can help public health officials target areas for control efforts (4) and track progress toward meeting the national health objectives set forth in Healthy People 2020 (5) . As of 2016, Healthy People 2020 objectives included reducing cancer deaths per 100,000 persons to 161.4 for all cancers, 45.5 for lung cancer, 20.7 for female breast cancer, 2.2 for cervical cancer, 14.5 for colorectal cancer, 2.3 for oropharyngeal cancer, 21.8 for prostate cancer, 2.4 for melanoma and reducing cancer incidence per 100,000 persons to 39.9 for colorectal cancer, 7.2 for cervical cancer, and 42.1 for late-stage female breast cancer (5) .
Cancer is a reportable disease in every state and thus all hospitals, physicians' offices, pathology laboratories, and other medical facilities are required to submit data on all reportable cancer diagnoses to a central cancer registry at the state or territorial level. A cancer registry is a database that contains individual records of all reportable cancer cases in a defined population and includes patient demographics, tumor characteristics (e.g., cancer site and pathology), and information about the notifying health provider or facility. Cancer control planners and others can identify variations in cancer rates by population subgroups and monitor trends over time to guide the planning and evaluation of cancer prevention and control programs and allocation of health resources.
Data Sources
Data about cancer incidence and mortality come from the official federal statistics on cancer, the USCS dataset (1) . The USCS dataset includes cancer incidence data from NPCR registries in 45 states and the District of Columbia (DC) (cancer incidence data from Puerto Rico and the U.S. Pacific Island Jurisdictions were not available for this analysis) and from SEER program registries in the remaining five states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and cancer mortality data from NVSS. Incidence data included in USCS have met publication criteria.
Incidence Data
The primary source of data on cancer incidence is medical records. Staff at medical facilities such as hospitals, doctors' offices, and pathology laboratories abstract data from patients' medical records, enter it into the facility's own cancer registry if it has one, and then send the data to the regional or state registry. The data then are sent to the central cancer registry in that state, district or territory. Every year the central cancer registries electronically submit incidence, demographic, and clinical data to NPCR or SEER. Both NPCR and SEER registries collect data using uniform data items and codes as documented by the North American Association of Central Cancer Registries (NAACCR). This uniformity ensures that data items collected by the two federal programs are comparable (6, 7) . Information on primary site and histology is coded according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) and categorized according to the revised SEER recodes dated January 27, 2003, which define standard groupings of primary cancer sites (https://seer.cancer.gov/ siterecode) (8) . Beginning with 2010 diagnoses, cases were first classified by anatomic site by using ICD-O-3; cases with hematopoetic histologies were further classified by using the 2008 World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues (9) . Data from the NPCR registries provided in this report were reported to CDC as of November 30, 2015. Data from SEER registries were reported to NCI as of November 1, 2015 .
NPCR and SEER cancer registries consider as reportable all incident cases with a behavior code of 2 (in situ, noninvasive) or 3 (malignant, primary site only) in ICD-O-3. Exceptions include in situ cancer of the cervix and all basal and squamous cell carcinomas of the skin, except for those on the skin of the genital organs (8) . Beginning with 2001 diagnoses, several cancers that are coded as malignant in ICD-O-3 were not coded as malignant in ICD-O-2 (6) . Additional information is provided in the USCS technical notes (https://www.cdc.gov/ cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf#namedd est=IncidenceDataSources).
Mortality Data
Cancer mortality statistics are based on information from all death certificates filed in the 50 states and DC and processed by NVSS at NCHS (10) . The cancer mortality data were compiled in accordance with WHO regulations, which specify that member nations classify and code causes of death in accordance with the current revision of the International Classification of Diseases (ICD) (11) . For consistency with the data on cancer incidence, the cancer sites in mortality data were grouped according to the revised SEER recodes dated January 27, 2003 (https://seer. cancer.gov/codrecode). Data for a specific calendar year are based on records of deaths that occurred during that calendar year and received by a particular date. Data in this report include mortality data for 2013 based on records of deaths that occurred during 2013 and received by NCHS as of June 30, 2015. Data in this report come from USCS, which includes cancer deaths during 1998-2013; cancer mortality data for 2014 are available at https://www.cdc.gov/nchs/nvss/deaths.htm. Additional information about mortality data is provided in the USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf#nameddest=MortalityDataSources).
Population Estimates
Population denominators are annual race-specific, ethnicityspecific, and sex-specific county population estimates modified by NCI in collaboration with CDC's NCHS from the U.S. Census intercensal (for July 1, 1999 July 1, -2009 ) and Vintage 2014 (for July 1, 2010 July 1, -2013 annual times series (12) . Modifications incorporated bridged single-race estimates that are derived from the original multiple race categories in the 2000 and 2010 censuses. For most states, population estimates as of July 1 of each year were used to calculate annual incidence rates because these estimates are presumed to reflect the average population of a defined geographic area for a calendar year. However, some county population estimates were adjusted to account for populations displaced along the Gulf Coast of Louisiana, Alabama, Mississippi, and Texas in the fall of 2005 by hurricanes Katrina and Rita. The national total population estimates were not affected by these adjustments. Other specific modifications included using additional local information to accurately estimate the native Hawaiian population and deriving population estimates for newly created counties in Colorado and Alaska. The modified county-level population estimates, summed to the state and national level, were used as denominators in rate calculations. Additional details about population data are available at https://seer.cancer.gov/ popdata/index.html.
Publication Criteria
Cancer incidence data are derived from state cancer registries that have high-quality cancer incidence data for individual (e.g., 2013) and combined (e.g., 1999-2013) years as demonstrated by meeting all of the following criteria on data quality for all cancer sites combined:
• case ascertainment is ≥90% (margin of error +5%) complete, • ≤5% of cases are ascertained solely on the basis of a death certificate, • ≤3% of cases are missing information on sex, • ≤3% of cases are missing information on age, • ≤5% of cases are missing information on race, and • ≥97% of the registry's records passed a set computerized edits that test the validity and logic of data components.
In this report, cancer incidence data for 2013 include data from DC and all states except Nevada, covering 99% of the US population, and data for 1999-2013 include data from all registries except Arkansas, DC, Mississippi, Nevada, South Dakota, Tennessee, and Virginia, covering 92% of the U.S. population. Additional information about USCS is available at available at https://www.cdc.gov/uscs/.
Interpreting Data Incidence Data
Each year, state cancer registries submit cancer cases for a new diagnosis year and an updated version of the previous year's cancer cases to CDC or NCI. Therefore, each year, when USCS data are published, updates to the previous year's data are published, using the most recent data submission and the most recent population data. Users of cancer incidence data published by federal agencies need to be mindful of the date of data submission for data used in their analyses.
Mortality Data
Cancer mortality statistics in USCS are influenced by the accuracy of information on the death certificate. Unlike incidence data, mortality data for a calendar year are considered complete when submitted and so are not updated after the aggregate data file is released. Mortality data for the entire United States refer only to deaths that occurred within the United States; data for geographic areas are provided by the decedent's place of residence.
Race and Ethnicity Data
Differences in rates among racial and ethnic populations should be interpreted with caution. For cancer incidence, race and ethnicity data are abstracted from medical records and grouped into categories (7). A study using SEER incidence data suggests that the quality of data on race/ethnicity in cancer registries is considered excellent for whites, blacks, and Asians/Pacific Islanders, good for Hispanics, and poor for American Indians/Alaska Natives (13) . When cancer mortality is reported, race and ethnic origin are recorded separately on the death certificate by the funeral director as provided by an informant or, in the absence of an informant, on the basis of observation (14) . Previous studies involving cancer mortality data demonstrate that death rates for whites and blacks generally are estimated accurately whereas death rates for Asians/Pacific Islanders, American Indians/Alaska Natives, and Hispanics are underestimated (2, 15) . Recent study involving evaluation of validity of race showed that classification of race and ethnicity on death certificates improved overtime for Asian/Pacific Islanders and Hispanics (now almost as good as whites and blacks), however, remained poor for American Indians/Alaska Natives (16) . For this reason, incidence and mortality data provided in this report might be underestimated for American Indians/Alaska Natives groups, possibly because of misclassification of race.
Three NPCR registries (Delaware, Kansas, and Kentucky) opted not to present state-specific Asian/Pacific Islander counts and rates. Six NPCR registries (Delaware, Kentucky, Massachusetts, Pennsylvania, North Dakota, and Virginia) opted not to present state-specific Hispanic (classified by the NAACCR Hispanic Identification [NHIA] Algorithm) counts and rates (17) . Cancer registries regularly link their database to the Indian Health Service patient registration dataset to reduce misclassification of race for American Indian/Alaska Native patients; in this report, 34 NPCR registries and all SEER registries linked cases diagnosed in 1999-2013. Six NPCR registries (Delaware, Illinois, Kansas, Kentucky, New Jersey, and New York) opted not to present state-specific American Indian/Alaska Native counts and rates. However, the aggregate national rates presented in this report include data for these registries, except that incidence rates by ethnicity exclude Virginia because ethnicity information was missing on 85% of cases from Virginia.
Population Coverage
The population coverage for incidence data varies by diagnosis year. Population coverage might be affected by the suppression of state incidence data if a state did not meet the publication criteria or did not submit data for that diagnosis year. In addition, state incidence data were suppressed in this report if <16 cases were reported or if the state requested that the data be suppressed. Additional information is provided by the USCS technical notes notes (https://www.cdc.gov/cancer/ npcr/uscs/pdf/uscs-2013-technical-notes.pdf#nameddest= CensusRegionPubCriteria). Mortality data from malignant neoplasms (i.e., cancers) as recorded in NVSS from the 50 states and DC are available in USCS, and thus 100% of the U.S. population is covered each year. However, state death data were suppressed in this report if <16 deaths were reported.
Suppression of Rates and Counts
When the numbers of cases or deaths used to compute rates are small, those rates tend to have poor reliability. Therefore, incidence and death rates and counts of <16 are not shown in tables and figures. The use of a threshold value for suppressing cells helps protect the confidentiality of patients by reducing or eliminating the risk for disclosure of their identity and helps avoid overreliance on unstable data. Additional information is provided in the USCS technical notes (https://www. cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes. pdf#nameddest=Suppression).
Highlights Incidence and Death Rates
In 2013, more than 1.5 million invasive cancers were diagnosed in the United States, an annual incidence rate of 439 cases per 100,000 persons (Table 1 ). In the same year, approximately 584,872 persons died of cancer nationally, an annual death rate of 163 deaths per 100,000 persons (Table 2) . Overall and for many cancer sites, males had higher incidence (Table 1 ) and death rates ( (Table 2) .
By state, overall (all cancer sites combined) cancer incidence rates in 2013 ranged from 364 to 512 cases per 100,000 persons (Table 3) , and overall cancer death rates ranged from 128 to 199 deaths per 100,000 persons (Table 4) . The Healthy People 2020 target (5) for overall cancer death rate (161.4 deaths per 100,000) has been reached in 21 states.
Cancer incidence (Table 5) and death (Table 6) rates increase with age. In 2013, among persons in the youngest age group (<15 years), 10,172 new cancer cases (rate: 17 cases per 100,000 persons) and 1,287 cancer deaths (rate: two deaths per 100,000 persons) were reported. Among persons aged ≥65 years, 851,505 new cancer cases (rate: 1,920 cases per 100,000 persons) and 407,558 cancer deaths (rate: 911 deaths per 100,000 persons) were reported. Overall, 55% of cancer cases and 70% of cancer deaths in 2013 occurred among persons aged ≥65 years.
In 2013, by race, blacks had the highest cancer incidence (Table 7) and death (Table 8) rates while American Indians/ Alaska Natives and Asians/Pacific Islanders had the lowest cancer death rates in the United States. By ethnicity, overall and for most cancer sites, Hispanics had lower cancer incidence (Table 9 ) and death rates (Table 10 ) than did non-Hispanics. Differences in cancer incidence ( Figure 1 ) and death ( Figure 2) rates by race and ethnicity might reflect differences in risk factors, screening, and treatment although rates among some populations might be under-or overestimated because of misclassification of race or ethnicity.
By state and site, cancer incidence rates in 2013 ranged from 69 to 131 per 100,000 males for prostate cancer, from 105 to 148 per 100,000 females for breast cancer, from 4 to 11 per 100,000 females for cervical cancer, from 26 to 93 per 100,000 persons for lung cancer, and from 32 to 49 per 100,000 persons for colorectal cancer (Figure 3) . By state and site, cancer death rates in 2013 ranged from 12 to 33 per 100,000 males for prostate cancer, from 15 to 30 per 100,000 females for breast cancer, from 1 to 4 per 100,000 females for cervical cancer, from 19 to 70 per 100,000 persons for lung cancer, and from 11 to 20 per 100,000 persons for colorectal cancer (Figure 4 ).
Time Trends in Incidence and Death Rates
On the basis of data from registries meeting data quality criteria during 2004-2013, cancer incidence counts (Table 11) and rates (Table 12 ) are presented by state and year. Time trends in cancer incidence rates are presented by cancer site, sex, and race ( Figure 5 ) and by cancer site, sex, and ethnicity ( Figure 6 ). Cancer incidence rates declined from 484 cancer cases per 100,000 population in 1999 to 432 cases in 2013. Figure 7 ) and by cancer site, sex, and ethnicity ( Figure 8 ). During 1999-2013, cancer death rates declined from 201 deaths per 100,000 persons in 1999 to 163 deaths in 2013; during the same period, death rates declined for each of the four most common cancers ( Figure 5 ). Cancer death counts (Table 13 ) and rates (Table 14) are presented by state and year.
National cancer surveillance data help public health officials track progress toward achieving the national cancer objectives set forth in Healthy People 2020 (18) . Differing rates of cancer by race, ethnicity, and state of residence indicate that for some populations, Healthy People 2020 objectives have already been achieved, whereas objectives for other populations have not been met. For the national cancer burden to be reduced and Healthy People 2020 targets to be met, behavioral and environmental factors that increase cancer risk must be reduced, and high-quality screening services, timely follow-up, and evidence-based treatments must be available and accessible to all persons. Cancer surveillance data can identify populations with high cancer rates that might benefit most from targeted cancer prevention and control efforts. Several effective evidence-based primary and secondary prevention measures, such as vaccination against infectious agents that cause cancer (i.e., hepatitis B virus and human papillomavirus), help with smoking cessation, and recommended cancer screening, when effectively implemented and sustained, could reduce the number of new cancer cases and prevent many cancerrelated deaths (19) . Evidence-based interventions can be implemented at both the individual level and the population level to reduce cancer risk factors, promote healthy living, and encourage cancer screening (3) . The impact of these efforts can be monitored using cancer surveillance data. information, see USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. § Race categories are not mutually exclusive from Hispanic origin. The Hispanic category excludes any cases from Virginia because information about ethnicity was missing on 85% of cases. Rates are not presented for persons of unknown or other race. Data for specified racial or ethnic populations other than white and black should be interpreted with caution. For more information, see USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf#n ameddest=IntRaceEthnicityData). ¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (all registries except Nevada, covering approximately 99% of the U.S. population). Caution should be used when comparing incidence and death rates because of the difference in population coverage. * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. § Rates are not presented for persons of unknown ethnicity. Data for specified ethnical populations should be interpreted with caution. For more information, see USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf#nameddest=IntRaceEthnicityData). ¶ Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined for all years, 1999-2013 (all registries except Arkansas, District of Columbia, Mississippi, Nevada, South Dakota, Tennessee, and Virginia, covering approximately 92% of the U.S. population). See registry-specific data quality information for all years, 1999-2013 (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf#nameddest=RegistriesPubCriteria). Caution should be used when comparing incidence and death rates because of potential differences in population coverage. Abbreviation: NOS = not otherwise specified. * Rates are the number of cases per 100,000 persons. For more information, see USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technicalnotes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Data are compiled from cancer registries that meet the data quality criteria for all invasive cancer sites combined (all registries except Nevada, covering approximately 99% of the U.S. population). ¶ Counts and rates are suppressed if <16 cases were reported in a specific category. Some counts and rates are suppressed as complementary cell suppression. Abbreviations: AI/AN = American Indian/Alaska Native; A/PI = Asian/Pacific Islander; NOS = not otherwise specified. * Rates are the number of cases per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups -Census P25-1130). For more information, see USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes.pdf ). † Invasive cancer excludes basal and squamous cell carcinomas of the skin except when these occur on the skin of the genital organs, and in situ cancers except urinary bladder. Urinary bladder cancer includes invasive and in situ. § Rates are not presented for persons of unknown or other race; therefore, categories do not sum to total. Data for specified racial populations other than white and black should be interpreted with caution. For more information, see USCS technical notes (https://www.cdc.gov/cancer/npcr/uscs/pdf/uscs-2013-technical-notes. pdf#nameddest=IntRaceEthnicityData). ** Counts and rates are suppressed if <16 cases were reported. 
